Independent · Non-profit · Open access

Mapping the therapeutic potential of existing medicines
— openly, and with the evidence attached.

The Open Source Medicine Foundation is an independent research non-profit. We map druggable targets, candidate repurposed compounds and registered clinical trials for 50+ chronic conditions, Long COVID and post-vaccine syndromes, and publish all of it free, with every source linked.

Explore candidate therapeutics by condition Read plain-language research notes

Research information for patients, clinicians and scientists — not medical advice.

400+peer-reviewed papers by our directors
50+conditions mapped
DailyPubMed & trial updates
100%open access, every source linked
Start here

What are you looking for?

Patients & caregivers

Plain-language summaries of the evidence

What the published research says about Long COVID, post-vaccine syndromes and chronic illness, written to be read without a medical degree, plus registered trials you can raise with your clinician.

Read the research notes →
Clinicians & researchers

Druggable targets, biomarkers and trials, graded by evidence

A daily-updated tracker: gene targets graded on DGIdb, Open Targets and ChEMBL evidence, biomarker atlases, registered trials and a repurposing explorer for candidate compounds. Downloadable and citable.

Open the Research Tracker →
Funders & partners

An integrated roadmap: discovery, testing, access, decisions

Open evidence infrastructure that connects candidate therapeutics, biomarkers, decentralised trials, regulatory access and decision intelligence. Open, collaborative and forkable by design.

See the roadmap →
Latest research notes

Our newest peer-reviewed work, explained

Each note summarises one of our publications in plain language and links to the full paper.

March 2026 · Environmental health

Endocrine disruptors: exposure and health effects

How common endocrine-disrupting chemicals affect thyroid, reproductive and metabolic hormones, and what the latest review says about exposure and remediation.

 February 2026 · Post-viral syndromes

Lactate, CO2 and fat oxidation in post-COVID and post-vaccine illness

A review of disrupted cellular energy production in post-acute COVID-19 and post-vaccination syndrome.

 February 2026 · Drug safety

Persistence of COVID-19 vaccine artifacts

Evidence that modified mRNA, spike protein and lipid nanoparticles remain detectable in tissues and fluids long after vaccination.

All research notes →  ·  Full research library →

Who we are

A small, independent foundation with a large research record

We take no pharmaceutical-industry funding. Everything we produce is published open access with its data and sources, so anyone can check it — and nothing here is a substitute for advice from your own clinician.

Team

Two directors, 400+ publications

Executive Director Matthew Halma (biophysics, pharmacoepidemiology) and Scientific Director Prof Jack A. Tuszynski (Allard Chair in Oncology, University of Alberta), with active clinical trial programmes.

Meet the team →
Track record

Cited by national advisory committees

Our work on post-acute COVID vaccination syndrome (PACVS) is cited by national advisory bodies, and our directors have published across candidate repurposed compounds for chronic conditions, post-viral syndromes, and environmental health and drug safety.

See our experience →
Featured initiative

PACVS Research Summit

An international consensus initiative bringing together researchers working on diagnostic criteria for post-acute COVID vaccination syndrome.

Visit the summit site →

The OSMF Network